Eliem Therapeutics ROE 2021-2024 | CLYM
Current and historical return on equity (ROE) values for Eliem Therapeutics (CLYM) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Eliem Therapeutics ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-06-30 |
$-0.07B |
$0.22B |
-47.62% |
| 2024-03-31 |
$-0.02B |
$0.11B |
-13.73% |
| 2023-12-31 |
$-0.04B |
$0.11B |
-31.25% |
| 2023-09-30 |
$-0.04B |
$0.11B |
-33.26% |
| 2023-06-30 |
$-0.05B |
$0.11B |
-36.51% |
| 2023-03-31 |
$-0.06B |
$0.12B |
-42.15% |
| 2022-12-31 |
$-0.05B |
$0.13B |
-32.86% |
| 2022-09-30 |
$-0.05B |
$0.13B |
-32.78% |
| 2022-06-30 |
$-0.05B |
$0.14B |
-31.20% |
| 2022-03-31 |
$-0.05B |
$0.16B |
-41.07% |
| 2021-12-31 |
$-0.05B |
$0.17B |
-72.35% |
| 2021-06-30 |
$-0.03B |
$-0.05B |
266.67% |
| 2021-03-31 |
$-0.03B |
$0.00B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
